|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LINC00910 |
Gene summary for LINC00910 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LINC00910 | Gene ID | 100130581 |
| Gene name | long intergenic non-protein coding RNA 910 | |
| Gene Alias | LINC00910 | |
| Cytomap | 17q21.31 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100130581 | LINC00910 | AEH-subject1 | Human | Endometrium | AEH | 2.62e-15 | 3.83e-01 | -0.3059 |
| 100130581 | LINC00910 | AEH-subject2 | Human | Endometrium | AEH | 8.08e-07 | 3.28e-01 | -0.2525 |
| 100130581 | LINC00910 | AEH-subject3 | Human | Endometrium | AEH | 1.00e-02 | 1.94e-01 | -0.2576 |
| 100130581 | LINC00910 | AEH-subject4 | Human | Endometrium | AEH | 4.48e-13 | 4.60e-01 | -0.2657 |
| 100130581 | LINC00910 | AEH-subject5 | Human | Endometrium | AEH | 6.64e-10 | 2.33e-01 | -0.2953 |
| 100130581 | LINC00910 | EEC-subject1 | Human | Endometrium | EEC | 6.90e-09 | 3.53e-01 | -0.2682 |
| 100130581 | LINC00910 | EEC-subject2 | Human | Endometrium | EEC | 1.32e-04 | 1.66e-01 | -0.2607 |
| 100130581 | LINC00910 | EEC-subject3 | Human | Endometrium | EEC | 3.09e-02 | 1.56e-01 | -0.2525 |
| 100130581 | LINC00910 | EEC-subject4 | Human | Endometrium | EEC | 2.54e-13 | 3.88e-01 | -0.2571 |
| 100130581 | LINC00910 | EEC-subject5 | Human | Endometrium | EEC | 1.86e-02 | 1.48e-01 | -0.249 |
| 100130581 | LINC00910 | HCC1 | Human | Liver | HCC | 1.73e-10 | 1.88e+00 | 0.5336 |
| 100130581 | LINC00910 | HCC2 | Human | Liver | HCC | 3.91e-14 | 9.72e-01 | 0.5341 |
| 100130581 | LINC00910 | HCC5 | Human | Liver | HCC | 1.23e-09 | 5.79e-01 | 0.4932 |
| 100130581 | LINC00910 | Pt13.b | Human | Liver | HCC | 1.15e-14 | 2.66e-01 | 0.0251 |
| 100130581 | LINC00910 | S014 | Human | Liver | HCC | 1.64e-05 | 1.82e-01 | 0.2254 |
| 100130581 | LINC00910 | S016 | Human | Liver | HCC | 6.39e-06 | 1.41e-01 | 0.2243 |
| 100130581 | LINC00910 | TD9 | Human | Lung | IAC | 4.70e-13 | 1.05e+00 | 0.088 |
| 100130581 | LINC00910 | RNA-P17T-P17T-2 | Human | Lung | IAC | 6.80e-05 | 6.37e-01 | 0.3371 |
| 100130581 | LINC00910 | RNA-P17T-P17T-4 | Human | Lung | IAC | 4.28e-05 | 7.18e-01 | 0.343 |
| 100130581 | LINC00910 | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.13e-06 | 8.54e-01 | 0.3385 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |